214750-77-3 Usage
Uses
Used in Pharmaceutical Synthesis:
BOC-D-PHE(4-NHBOC)-OH is used as an intermediate for the preparation of doxorubicin-formaldehyde peptide conjugates, which target αvβ3 integrin. This application is crucial in the development of targeted therapies for various diseases, including cancer.
Used in Caspases Inhibition:
BOC-D-PHE(4-NHBOC)-OH is also utilized in the synthesis of peptide acyloxymethyl ketones, which act as selective caspases inhibitors. These inhibitors play a significant role in regulating cellular processes and have potential applications in the treatment of various conditions, such as neurodegenerative diseases and cancer.
Used in the Chemical Industry:
In the chemical industry, BOC-D-PHE(4-NHBOC)-OH may be used as a building block for the synthesis of more complex molecules with specific functions and properties. Its versatility as an intermediate allows for the creation of a wide range of products with potential applications in various fields.
Used in Research and Development:
BOC-D-PHE(4-NHBOC)-OH is an essential compound in the field of research and development, where it is employed to study the structure-activity relationships of various bioactive molecules. This knowledge can lead to the discovery of new therapeutic agents and a better understanding of molecular interactions.
Check Digit Verification of cas no
The CAS Registry Mumber 214750-77-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,7,5 and 0 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 214750-77:
(8*2)+(7*1)+(6*4)+(5*7)+(4*5)+(3*0)+(2*7)+(1*7)=123
123 % 10 = 3
So 214750-77-3 is a valid CAS Registry Number.
InChI:InChI=1/C29H30N2O6/c1-29(2,3)37-28(35)30-19-14-12-18(13-15-19)16-25(26(32)33)31-27(34)36-17-24-22-10-6-4-8-20(22)21-9-5-7-11-23(21)24/h4-15,24-25H,16-17H2,1-3H3,(H,30,35)(H,31,34)(H,32,33)/t25-/m1/s1
214750-77-3Relevant articles and documents
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
Geurink, Paul P.,Van Der Linden, Wouter A.,Mirabella, Anne C.,Gallastegui, Nerea,De Bruin, Gerjan,Blom, Annet E. M.,Voges, Mathias J.,Mock, Elliot D.,Florea, Bogdan I.,Van Der Marel, Gijs A.,Driessen, Christoph,Van Der Stelt, Mario,Groll, Michael,Overkleeft, Herman S.,Kisselev, Alexei F.
supporting information, p. 1262 - 1275 (2013/03/29)
Proteasomes degrade the majority of proteins in mammalian cells by a concerted action of three distinct pairs of active sites. The chymotrypsin-like sites are targets of antimyeloma agents bortezomib and carfilzomib. Inhibitors of the trypsin-like site se
